Clinical trial
Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in…
NCT00326599 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00326599 |
|---|---|
| Title | Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, cediranib maleate, gemcitabine hydrochloride |
| Enrollment | 101 |
| Start date | Jun 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Feb 1, 2010 |
| First posted | May 17, 2006 |
| Last update posted | Mar 21, 2017 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: